Purchase this article with an account.
Alexandros Deligiannidis, Jose Lorenzo Carrero; Effects of antiangiogenic treatment in vitreomacular adhesion in patients with diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2108.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe the effect of antiangiogenic treatment to the progression of posterior vitreous detachment in diabetic patients with macular edema.
Retrospective study of all diabetic patients with macular edema who were treated with antiangiogenic treatment in two institutions during a 3-year period. Baseline ophthalmic and follow-up examination included evaluation of the vitreoretinal interface with OCT.
There were 145 patients with gradable OCT exams: Initially; 35 (24%) patients had no detectable PVD, 39 (26%) patients with broad VMA, 44 (30%) with focal VMA, 11 (7,5%), with no VMA but posterior vitreous attachment to the optic disc, and 16 (11%) patients with complete PVD. During follow-up, there were 47 (32%) patients who experienced progression of the vitreous detachment. Patients who experienced progression of the vitreomacular detachment were likely to have been treated with more injections (mean: 6,15) than patients who did not progress (mean: 3,32). (unpaired t-test p=0,001). There were no differences concerning visual outcome and reduction of the macular thickness.
Antiangiogenic treatment may induce progression of the posterior vitreous detachment at the posterior vitreoretinal interface in diabetic patients with macular edema.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only